Ensartinib
- Generic Name
- Ensartinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27Cl2FN6O3
- CAS Number
- 1370651-20-9
- Unique Ingredient Identifier
- SMA5ZS5B22
- Background
Ensartinib is under investigation in clinical trial NCT03420508 (Treating Patients With Melanoma and ALK Alterations With Ensartinib).
- Indication
用于此前接受过克唑替尼治疗后进展的或者对克唑替尼不耐受的间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的二线治疗。
Treating Patients With Melanoma and ALK Alterations With Ensartinib
- Conditions
- Melanoma
- Interventions
- Diagnostic Test: ALKATI by Customized Nanostring Assay
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03420508
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
- Conditions
- Recurrent Malignant GliomaRecurrent NeuroblastomaMalignant Solid NeoplasmRecurrent MedulloblastomaRecurrent Rhabdoid TumorRecurrent Soft Tissue SarcomaRefractory Malignant Germ Cell TumorRefractory Malignant Solid NeoplasmRefractory Rhabdoid TumorAdvanced Malignant Solid Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Bone ScanProcedure: Computed TomographyOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingOther: Pharmacological StudyProcedure: Positron Emission TomographyProcedure: Radionuclide ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 98
- Registration Number
- NCT03213652
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Conditions
- Advanced Malignant Solid NeoplasmJuvenile XanthogranulomaLangerhans Cell HistiocytosisMalignant GliomaRecurrent Childhood RhabdomyosarcomaRecurrent Ewing SarcomaRecurrent OsteosarcomaRecurrent Primary Central Nervous System NeoplasmRefractory HepatoblastomaRefractory Medulloblastoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionOther: Laboratory Biomarker AnalysisProcedure: Bone Marrow Aspiration and BiopsyProcedure: Mutation Carrier ScreeningProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Pharmacological StudyProcedure: Radionuclide ImagingProcedure: Positron Emission TomographyProcedure: X-Ray Imaging
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1376
- Registration Number
- NCT03155620
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
- Conditions
- Solid TumorNon-Small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02959619
- Locations
- 🇨🇳
Sun yat-sen Univerisity Cancer Center, Guanzhou, Guangdong, China
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung CancerCarcinomaNSCLC
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 2
- Registration Number
- NCT02898116
- Locations
- 🇺🇸
Research Facility, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.